These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 24107267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 4. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB.
    Headache; 2024 Jun; 64(7):838-848. PubMed ID: 38982666
    [Abstract] [Full Text] [Related]

  • 5. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.
    J Headache Pain; 2018 Feb 05; 19(1):13. PubMed ID: 29404713
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.
    J Headache Pain; 2017 Dec 05; 18(1):78. PubMed ID: 28766236
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT, Jaffri SF.
    Headache; 2009 Dec 05; 49(10):1466-78. PubMed ID: 19912346
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.
    Neurol Sci; 2017 Oct 05; 38(10):1779-1789. PubMed ID: 28726049
    [Abstract] [Full Text] [Related]

  • 17. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 05; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 18. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
    Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S.
    BMC Neurol; 2015 Jul 03; 15():100. PubMed ID: 26133547
    [Abstract] [Full Text] [Related]

  • 19. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.